The new analysis includes data from seven studies that were not part of the previous FDA analysis, including two large pediatric depression trials that were unavailable three years ago.
Researchers analyzed data on 5,310 children and teenagers from 27 studies. They found that for every 100 youths treated with antidepressants, about one additional child experienced worsening suicidal feelings above what would have happened without drug treatment. The FDA analysis had found an added risk affecting about two in 100 patients.
There were no suicides in any of the studies. The antidepressants included Prozac, Paxil, Zoloft, Celexa, Lexapro, Effexor, Serzone, and Remeron.
"The medications are safe and effective and should be considered as an important part of treatment," said study co author Dr. David Brent of the University of Pittsburgh School of Medicine.
Antidepressants worked best when used to treat anxiety, the analysis found. They worked moderately well treating obsessive-compulsive disorders. They worked less well, but were still effective, in treating depression.
Adolescents responded better than children to treatment for depression and anxiety, the researchers found. They also found that only Prozac worked better than dummy pills in depressed children younger than 12.
In the studies involving depression, 61 percent of patients improved while on antidepressants. But 50 percent of depressed patients taking dummy pills also improved.
Among young patients with obsessive-compulsive disorders, 52 percent improved on antidepressants, compared to with 32 percent who improved on dummy pills.
And in the studies of anxiety disorders, 69 percent improved on antidepressants and 39 percent improved on dummy pills.
Effectiveness of the drugs was measured in the studies using widely accepted rating scales. The analysis appears in today's Journal of the American Medical Association.
